Palbociclib Gains HER2+ Breast Cancer Maintenance Indication M. Alexander Otto, PA, MMSc June 25, 2026

https://www.medscape.com/viewarticle/palbociclib-gains-her2-breast-cancer-maintenance-indication-2026a1000ljr?src= The FDA has approved palbociclib (Ibrance, Pfizer) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of hormone receptor-positive (HR+), HER2+ locally advanced or metastatic breast cancer following induction treatment. In the phase 3 approval trial, PATINA, adding palbociclib to standard anti-HER2 and endocrine therapies for maintenance resulted in a 24% reduction in the risk for disease progression.